Skip to main content
AACI
NASDAQ Real Estate & Construction

Armada III Signs $750M Definitive Deal to Take Brains Bioceutical Public via Nasdaq

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Real Estate
Sentiment info
Positive
Importance info
9
Price
$10.105
Mkt Cap
$343.871M
52W Low
$9.74
52W High
$10.111
52W Position info
3.7% above low
Off High info
at 52W high
Rel. Volume info
17× avg
Market data snapshot near publication time

AACI is trading near its 52-week low of $9.74 (3.7% above the low) on elevated volume (17× avg).

Summary

Armada Acquisition Corp. III signed a definitive agreement to combine with Brains Bioceutical at a $750.0 million enterprise value, with Brains holders rolling 100% of their equity and up to 14,705,882 earnout shares tied to $12.50 and $15.00 share-price hurdles. The deal needs up to $100.0 million of new financing and is targeted to close in the second quarter of 2027.


Key Events · M&A and Partnerships · AACI

  • Definitive Deal at $750M Enterprise Value

    Brains Bioceutical shareholders receive newly issued PubCo shares based on a $750.0 million enterprise value divided by a $10.20 per share reference value, with 100% of Brains equity rolling into the combined company.

  • Earnout Adds 14.7M Contingent Shares

    14,705,882 PubCo shares sit in escrow, half releasing if the VWAP reaches $12.50 and half at $15.00 for 20 of 30 trading days between six months and three years after closing; unreleased shares are forfeited.

  • Up to $100M Financing Still Needed

    The parties must market up to $100.0 million of Transaction Financings before closing, and the investor presentation states there is no minimum cash condition and no financing has been committed.

  • Going-Concern Warning Disclosed

    The investor presentation states Brains' financial statements include disclosure of a material uncertainty that may cast significant doubt on its ability to continue as a going concern, and that it carries substantial current indebtedness.


Analysis · AACI · Real Estate & Construction

This definitive agreement turns a cash-shell SPAC into a cannabinoid pharmaceutical company. Brains is valued at a $750.0 million enterprise value, priced off a $10.20 per share reference value, with existing Brains holders rolling 100% of their equity and receiving 14,705,882 earnout shares that only release if PubCo trades at $12.50 and then $15.00 for 20 of 30 trading days. The deal is not funded: up to $100.0 million of Transaction Financings must still be raised, there is no minimum cash condition, and the investor presentation discloses a material uncertainty about Brains' ability to continue as a going concern. Armada's $251.6 million trust is the only committed cash, and every redeemed public share reduces what reaches the combined company's balance sheet. Closing is targeted for the second quarter of 2027 and requires Armada and Brains shareholder votes, a British Columbia Supreme Court order, an effective Form F-4 and Nasdaq listing approval, with a June 30, 2027 outside date.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AACI was trading at $10.11 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $343.9M. The 52-week trading range was $9.74 to $10.11. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AACI - Latest Insights

AACI
Nov 05, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $10.09
Real-time Price: $10.11 info
Change: +$0.020 (+0.20%) info
Market Cap: $344.042M info